Alaunos Therapeutics, Inc.'s highest-paid named officer for fiscal year 2024, Former Chief Executive Officer Kevin Boyle, was paid $392,500 (SEC filing 0001193125-25-123677 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$392,500 Kevin Boyle total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Boyle | $317,500 | $0 | $0 | $0 | $0 | $0 | $75,000 | $392,500 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kevin Boyle | $392,500 | $1,986,946 | — | ↓ −1,594,446 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Alaunos Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TCRT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Groenewald | Option | 1,406 | 2.42 | — |
| Lackey | Option | 750 | 75 | — |
| Dale Curtis Hogue | Option | 667 | 10.5 | — |
| Lackey | Option | 1,406 | 2.42 | — |
| Lackey | Option | 540 | 315 | — |
| Dale Curtis Hogue | Option | 334 | 18 | — |
| Lackey | Option | 617 | 183 | — |
The company uses base salaries to recognize experience, skills, and responsibilities, reviewing them annually to align with market levels. Long-term equity incentive compensation, specifically stock options, is considered a critical component to link executive interests with stockholders and incentivize performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer and Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Holger WeisIndependent · Audit · Compensation | $109,000 | $0 | $23,090 | — | — | $132,090 |
| Robert J. HofmeisterIndependent · Compensation · Corporate Governance and Nominating | 71,000 | 0 | 12,815 | — | — | 83,815 |
| Jaime VieserIndependent · Audit · Corporate Governance and Nominating | 68,000 | 0 | 12,815 | — | — | 80,815 |
| Dale Curtis HogueIndependent | 2,740 | 0 | 0 | — | — | 2,740 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $250,740 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $250,740 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Alaunos Therapeutics, Inc. | 2024 | Kevin Boyle | $317,500 | $0 | $0 | $0 | $392,500 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Boyle | DEF 14A | 2025-05-21 | 0001193125-25-123677 | Section “Summary Compensation Table”. As printed: 392,500. Filing ↗machine: r8 · c26 · span 406947–406954 |
| 2 | Section 08, Holger Weis | DEF 14A | 2025-05-21 | 0001193125-25-123677 | Section “Director Compensation”. As printed: 132,090. Filing ↗machine: span 582437–582444 |
| 3 | Section 08, Robert J. Hofmeister | DEF 14A | 2025-05-21 | 0001193125-25-123677 | Section “Director Compensation”. As printed: 83,815. Filing ↗machine: span 585116–585122 |
| 4 | Section 08, Jaime Vieser | DEF 14A | 2025-05-21 | 0001193125-25-123677 | Section “Director Compensation”. As printed: 80,815. Filing ↗machine: span 583782–583788 |
| 5 | Section 08, Dale Curtis Hogue | DEF 14A | 2025-05-21 | 0001193125-25-123677 | Section “Director Compensation”. As printed: 2,740. Filing ↗machine: span 580327–580332 |
| 6 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 7 | Section 09b board cost (computed) | Computed | — | — | Cash 250,740 + equity 0 + all other 0 = 250,740, summed across the director compensation table rows.machine: formula: Σ = 250,740 |
| 8 | Alaunos Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-05-21 | 0001193125-25-123677 | CEO total compensation as printed in Alaunos Therapeutics, Inc.'s own proxy. As printed: 392,500. Filing ↗machine: r8 · c26 · span 406947–406954 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat